CARLOS
TAXONERA SAMSO
Profesor asociado
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, EspañaPublicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (25)
2022
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
Therapeutic Advances in Gastroenterology, Vol. 14
-
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease
Gastroenterologia y Hepatologia, Vol. 44, Núm. 1, pp. 51-66
-
Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42
2020
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854
-
Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: the Practicrohn study
Expert Review of Gastroenterology and Hepatology, Vol. 13, Núm. 8, pp. 807-813
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
-
Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: Results from the PRACTICROHN study
Gastroenterology Report, Vol. 7, Núm. 6, pp. 411-418
2018
-
Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279
2017
-
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation
Digestive Diseases and Sciences, Vol. 62, Núm. 2, pp. 481-490
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
-
Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease
Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800
-
Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131
-
Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study
Inflammatory Bowel Diseases, Vol. 23, Núm. 10, pp. 1840-1846
2016
-
Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn's disease
Journal of Crohn's and Colitis, Vol. 10, Núm. 6, pp. 657-662